These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 26059976)

  • 1. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
    Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
    Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
    Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
    J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid treatment in children with osteogenesis imperfecta.
    Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
    Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
    Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
    Bone; 2016 May; 86():53-7. PubMed ID: 26927310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
    Arikoski P; Silverwood B; Tillmann V; Bishop NJ
    Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height.
    Robinson ME; Trejo P; Palomo T; Glorieux FH; Rauch F
    J Bone Miner Res; 2019 Dec; 34(12):2198-2204. PubMed ID: 31356699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
    Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.